Pralidoxime - Warnings and Precautions
The following warnings and precautions are taken directly from the US FDA-approved drug label for Pralidoxime. This is the same information dispensing pharmacists read.
5 WARNINGS AND PRECAUTIONS Cardiovascular (CV) Risks: Tachycardia, palpitations, premature ventricular contractions, flutter, fibrillation, etc.
Use caution in patients with known CV disease or conduction problems.
Heat Injury: May inhibit sweating and lead to hyperthermia; avoid excessive exercising and heat exposure.
Acute Glaucoma: May precipitate in susceptible individuals.
Urinary Retention : Administer with caution in patient with bladder outflow obstruction.
Pyloric Stenosis: May convert into complete obstruction.
Exacerbation of Chronic Lung Disease: Atropine may cause inspissation of bronchial secretions and formation of dangerous viscid plugs in individuals with chronic lung disease; monitor respiratory status.
5.1 Cardiovascular Risks Cardiovascular adverse reactions reported in the literature for atropine include, but are not limited to, sinus tachycardia, palpitations, premature ventricular contractions, atrial flutter, atrial fibrillation, ventricular flutter, ventricular fibrillation, cardiac syncope, asystole, and myocardial infarction.
In patients with a recent myocardial infarction and/or severe coronary artery disease, there is a possibility that atropine-induced tachycardia may cause ischemia, extend or initiate myocardial infarcts, and stimulate ventricular ectopy and fibrillation.
DuoDote should be used with caution in patients with known cardiovascular disease or cardiac conduction problems.
5.2 Heat Injury Atropine may inhibit sweating which, in a warm environment or with excessive exercise, can lead to hyperthermia and heat injury.
To the extent feasible, avoid excessive exercise and heat exposure [see Overdosage ].
5.3 Acute Glaucoma Atropine should be administered with caution in patients at risk for acute glaucoma.
5.4 Urinary Retention Atropine should be administered with caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.
5.5 Pyloric Stenosis Atropine should be administered with caution in patients with partial pyloric stenosis because of the risk of complete pyloric obstruction.
5.6 Exacerbation of Chronic Lung Disease Atropine may cause inspissation of bronchial secretions and formation of dangerous viscid plugs in individuals with chronic lung disease.
Respiratory status should be monitored in individuals with chronic lung disease following administration of DuoDote.
Applies to YOU?
Some warnings apply only to specific age groups, health conditions, or other medicines. Ask GoDavaii AI to filter which of these 17+ warnings apply to your profile.
Ask Health AI \u2192